Synopsis Day 2: 2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
https://worldmedicalinnovation.org/
https://worldmedicalinnovation.org/https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg
Announcement
Aviva Lev-Ari, PhD, RN,
Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME
@pharma_BI
@AVIVA1950
- Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
- Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies
All TWEETS from LPBI’s Twitter.com handles at
#WMIF18
Tuesday, April 24, 2018
Nuance Foyer
NVIDIA Ballroom
NVIDIA Ballroom
Will AI Bend the Cost and Access Curve
Historical barriers have driven increased medical costs and decreasing access since the 1960s. The “Iron Triangle of Healthcare” continues to represent a tenuous balance of quality, cost and accessibility – economists have lamented attempts to optimize one characteristic at the expense of the others. The accumulation of innovations in care delivery (e.g. shift to lower cost providers and settings), population management, value based reimbursement and hospital administration are having a measurable effect. Can AI based technologies accelerate the pace of innovation and finally bend the cost and access curves in the US?
NVIDIA Ballroom
Drug Therapy Redefined Through Machine Learning
The drug development process is highly complex and has many drivers. The panel will discuss the strategic impact of AI on the entire process and the implications for healthcare overall. How will the combination of factors – research strategy, drug development, regulatory approvals, reimbursement and clinical effectiveness – be influenced by the implementation of AI. Panelists will discuss short and mid-term prospects and whether AI will ultimately lead to a restructuring of the pharma model to develop new therapies.
NVIDIA Ballroom
Nuance Foyer
NVIDIA Ballroom
Data Engineering in Healthcare: Liberating Value
The promise of machine learning and big data in in healthcare seems boundless – but healthcare data is massive and complex, and organizing and managing this data is the first step to an AI-empowered healthcare system. Technology giants are investing in solutions to overcome these data engineering challenges, but with many visions of the future of healthcare data jockeying for dominance, what will the future of healthcare data really look like? Can we finally liberate the value of data for patient care? And how will it happen?
NVIDIA Ballroom
1:1 Fireside Chat: Jensen Huang, CEO, NVIDIA
GE Ballroom
GE Ballroom
1:1 Fireside Chat: Paul Ricci, Former Chairman and CEO of Nuance Communications
NVIDIA Ballroom
AI and Gene Sequencing
Gene sequencing technology has evolved considerably over the last 10 years, dramatically decreasing the cost to sequence a human genome. As the costs associated with the technical assay continue to decrease, data interpretation and reporting has become the new bottleneck. Can AI and ML based approaches be applied to better understand how genetic mutations play a role in diseases like cancer – where the high rate of mutation makes treatment challenging? And will continued democratization of genetic information help to accelerate the pace of innovation in the field?
NVIDIA Ballroom
Tangible Returns on the AI Value Proposition
Fueled by billions in venture investments, hundreds of new companies have emerged worldwide to develop and apply AI in health care. Beyond the US, China’s high AI priority has resulted in a vast array of technology driven start-ups. Global investors will discuss which area of machine learning will have the earliest meaningful impact? How do investors critically assess differentiation in such a crowded field? How are investment priorities set among the many divergent categories where AI will take hold?
NVIDIA Ballroom
CEO Roundtable: The AI Opportunity as Foundational Change
Chief executives share perspectives on the impact of AI on their respective companies and industry segments. How prominently does AI figure into current investment strategies? And how are they measuring return on existing investments in AI? Panelist will be asked to take a position on whether AI is a truly transformational technology.
NVIDIA Ballroom
NVIDIA Ballroom
Regulating AI in Healthcare, Requirements and Challenges
The increasing application of AI in health products puts pressure on the historical model of regulation – among them the agile development cycles and continuous learning environment that support AI / machine learning based algorithms. Panelists will discuss the regulatory approaches including the FDA’s recently announced Software Precertification pilot program.
NVIDIA Ballroom
AI in Hospital Environments: The Learning Provider
Health systems are actively evaluating strategies to drive efficiency throughout hospital operations. The deployment of AI based technologies to automate organizational tasks (e.g. medical coding / billing, prior authorizations) and optimize resource utilization (e.g. smart scheduling, no-show prediction) promises to help hospital systems adapt to changing macro-economic factors. This panel will discuss the role of AI in hospital operations and assess various approaches to reduce healthcare administration costs and increase efficiency.
GE Foyer
Leave a Reply